Please login to the form below

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

Solid Q1 results lift Pfizer as it waits for pipeline boost

Also among the top performers was rheumatoid arthritis drug Xeljanz (tofacitinib), which posted a healthy 30% rise in sales to $423m thanks to new indications in psoriatic arthritis and ulcerative colitis.

Latest news

Gilead and Galapagos close in on filing for Xeljanz rival

If approved, filgotinib would likely be the fourth JAK inhibitor for RA after Pfizer’s $1.8bn seller Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib), and AbbVie’s upadacitinib which has
EMA could follow FDA’s Xeljanz blood clot warning

Xeljanz is currently approved in both the US and EU for patients with rheumatoid arthritis (RA) and psoriatic arthritis, but at an authorised dose of 5mg, twice daily. ... The results aren’t great news for Pfizer and Xeljanz, which has been plagued
New data keeps AbbVie’s star pipeline therapies on track

follow-up to its marketed JAK inhibitor Xeljanz (tofacitinib). ... And for good measure Pfizer is developing a topical formulation of Xeljanz for atopic dermatitis, an approach also taken by Torii Pharma with its phase II candidate JTE-052.
BMS psoriasis drug hits the mark in phase II

Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
Gilead and Galapagos JAK contender scores in RA trial

The first JAK inhibitor on the market is Pfizer’s Xeljanz (tofacitinib) and already earns in excess of $1bn a year in RA revenues.

More from news
Approximately 18 fully matching, plus 46 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Medical Writer/ Senior Medical Writer opportunities – Macclesfie...: competitive salary and benefits package

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Medical Writer: Salary TBC

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

What are you doing, Dave?: Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health: Ill informed patients make poor health decisions...
Secrets of Pharma Advertising: If the goal of branding is to be different, why do so many Pharma brand ads look the same?...